Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure

被引:40
|
作者
Gager, Gloria M. [1 ,2 ]
von Lewinski, Dirk [3 ]
Sourij, Harald [4 ]
Jilma, Bernd [2 ]
Eyileten, Ceren [5 ]
Filipiak, Krzysztof [6 ]
Huelsmann, Martin
Kubica, Jacek [7 ]
Postula, Marek [5 ]
Siller-Matula, Jolanta M. [1 ,5 ]
机构
[1] Med Univ Vienna, Div Cardiol, Dept Internal Med 2, Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria
[3] Med Univ Graz, Div Cardiol, Dept Internal Med, Graz, Austria
[4] Med Univ Graz, Div Endocrinol & Diabetol, Dept Internal Med, Interdisciplinary Metab Med Trials Unit, Graz, Austria
[5] Med Univ Warsaw, Dept Expt & Clin Pharmacol, Ctr Preclin Res & Technol CEPT, Warsaw, Poland
[6] Med Univ Warsaw, Chair & Dept Cardiol 1, Warsaw, Poland
[7] Nicolaus Copernicus Univ, Coll Med, Bydgoszcz, Poland
基金
奥地利科学基金会;
关键词
Heart failure; SGLT2; inhibitors; Ion homeostasis; Oxidative stress; Inflammation; Fibrosis; Endothelial dysfunction; REDUCED EJECTION FRACTION; MYOCARDIAL-INFARCTION; NA+/H+ EXCHANGER; MITOCHONDRIAL DYSFUNCTION; CARDIOVASCULAR OUTCOMES; EMPAGLIFLOZIN IMPROVES; INTRACELLULAR NA+; CYTOSOLIC NA+; NADPH OXIDASE; CALCIUM;
D O I
10.1016/j.biopha.2021.112169
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Sodium-glucose cotransporter 2 (SGLT2) inhibitors present a class of antidiabetic drugs, which inhibit renal glucose reabsorption resulting in the elevation of urinary glucose levels. Within the past years, SGLT2 inhibitors have become increasingly relevant due to their effects beyond glycemic control in patients with type 2 diabetes (T2DM). Although dedicated large trials demonstrated cardioprotective effects of SGLT2 inhibitors, the exact mechanisms responsible for those benefits have not been fully identified. Alterations in Ca2+ signaling and oxidative stress accompanied by excessive reactive oxygen species (ROS) production, fibrosis and inflammatory processes form cornerstones of potential molecular targets for SGLT2 inhibitors. This review focused on three hypotheses for SGLT2 inhibitor-mediated cardioprotection: ion homeostasis, oxidative stress and endothelial dysfunction.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
    Theofilis, Panagiotis
    Oikonomou, Evangelos
    Tsioufis, Konstantinos
    Tousoulis, Dimitris
    LIFE-BASEL, 2023, 13 (02):
  • [22] SGLT2 inhibitors for alleviating heart failure through non-hypoglycemic mechanisms
    Chen, Ya-ru
    Zhu, Fang-yuan
    Zhou, Rong
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [23] Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
    Palmiero, Giuseppe
    Cesaro, Arturo
    Vetrano, Erica
    Pafundi, Pia Clara
    Galiero, Raffaele
    Caturano, Alfredo
    Moscarella, Elisabetta
    Gragnano, Felice
    Salvatore, Teresa
    Rinaldi, Luca
    Calabro, Paolo
    Sasso, Ferdinando Carlo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (11)
  • [24] Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects
    Dyck, Jason R. B.
    Sossalla, Samuel
    Hamdani, Nazha
    Coronel, Ruben
    Weber, Nina C.
    Light, Peter E.
    Zuurbier, Coert J.
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2022, 167 : 17 - 31
  • [25] SGLT2 inhibitors in heart failure with reduced ejection fraction
    Uday Sankar Das
    Aritra Paul
    Suvro Banerjee
    The Egyptian Heart Journal, 73
  • [26] SGLT2 Inhibitors and Their Effect on Metabolism in Patients With Heart Failure
    Wiggers, Henrik
    CIRCULATION-HEART FAILURE, 2024, 17 (11)
  • [27] SGLT2 INHIBITORS: RATIONALE AND PERSPECTIVES OF USE IN HEART FAILURE
    Kobalava, Zh. D.
    Lazarev, P., V
    Villevalde, S. V.
    KARDIOLOGIYA, 2018, 58 (02) : 42 - 54
  • [28] Pharmacy projects target SGLT2 inhibitors for heart failure
    Traynor, Kate
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2023, 80 (07) : 404 - 405
  • [29] Adherence and Persistence to SGLT2 Inhibitors in Patients With Heart Failure
    Kono, Shogo
    Moon, Jungyeon
    Chong, Alice
    Fang, Jiming
    Ko, Dennis T.
    Austin, Peter
    Atzema, Clare
    Naimark, David
    Udell, Jacob A.
    Stukel, Therese
    Tu, Karen
    Booth, Gillian
    Jackevicius, Cynthia
    CIRCULATION, 2023, 148
  • [30] SGLT2 inhibitors: a new pillar of the heart failure regimen
    DeSa, Travis
    Gong, Timothy
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2021, 22 (04) : 1253 - 1269